Sort   by:  
 Page size 
MetabolomicsHypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239
Background: Elevated choline kinase alpha (ChoK) levels are observed in most solid tumors, including glioblastomas (GBM), and ChoK inhibitors have demonstrated limited efficacy in GBM models. Given that hypoxia is associated with resistance to GBM therapy, we hypothesized that tumor hypoxia c...
2024-06-18 | MTBLS6212 | MetaboLights
MetabolomicsThe pyruvate kinase, a metabolic sensor powering glycolysis, drives the metabolic control of DNA replication

BACKGROUND: In all living organisms, DNA replication is exquisitely regulated in a wide range of growth conditions to achieve timely and accurate genome duplication prior to cell division. Failures in this regulation cause DNA damage with potentially disastrous consequences ...

2022-04-19 | MTBLS4415 | MetaboLights
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
MetabolomicsDissection of two routes to naïve pluripotency using different kinase inhibitors
Embryonic stem cells (ESCs) can be maintained in the naïve state through inhibition of Mek1/2 and Gsk3 (2i). A relevant effect of 2i is the inhibition of Cdk8/19, which are negative regulators of the Mediator complex, responsible for the activity of enhancers. Inhibition of Cdk8/19 (Cdk8/19i) stimul...
2021-02-10 | MTBLS301 | MetaboLights
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
MetabolomicsEffects of the Kinase Inhibitor Sorafenib on Liver Metabolism In Vivo using Non-targeted Metabolomics Analysis tissue).
Not available
ORGANISM(S): Mus musculus 
ST000577 | MetabolomicsWorkbench
MetabolomicsEffects of the Kinase Inhibitor Sorafenib on Heart Metabolism In Vivo using Non-targeted Metabolomics Analysis tissue).
Not available
ORGANISM(S): Mus musculus 
ST000576 | MetabolomicsWorkbench
MetabolomicsEffects of the Kinase Inhibitor Sorafenib on Muscle Metabolism In Vivo using Non-targeted Metabolomics Analysis tissue).
Not available
ORGANISM(S): Mus musculus 
ST000575 | MetabolomicsWorkbench
MetabolomicsEffects of the Kinase Inhibitor Sorafenib on Serum Metabolism In Vivo using Non-targeted Metabolomics Analysis tissue).
Not available
ORGANISM(S): Mus musculus 
ST000574 | MetabolomicsWorkbench
MetabolomicsThe phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 inhibitor 3PO is a modulator of neutrophil metabolism, ROS production and NET release
Neutrophils are key effector leukocytes of the innate immune system and play a pivotal role in defending the host against microbial infections. Recent studies have identified a crucial link between glycolysis and neutrophil cellular functions. We have investigated in human neutrophils, the intricate...
2025-08-14 | MTBLS6215 | MetaboLights
Sort   by:  
 Page size